Adaptimmune Therapeutics plc revenue for the last year amounted to 60.28 M USD, the most of which — 60.28 M USD — came from its highest performing source at the moment, Novel Cell Therapies, the year earlier bringing 27.15 M USD. The greatest contribution to the revenue figure was made by United Kingdom — last year it brought Adaptimmune Therapeutics plc 60.28 M USD, and the year before that — 27.15 M USD.